Mabion SA
WSE:MAB
Intrinsic Value
Mabion SA is a biotechnology company, which engages in the development and manufacture of biotech drugs. [ Read More ]
The intrinsic value of one MAB stock under the Base Case scenario is 12.65 PLN. Compared to the current market price of 18.78 PLN, Mabion SA is Overvalued by 33%.
Valuation Backtest
Mabion SA
Run backtest to discover the historical profit from buying and selling MAB stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Mabion SA
Current Assets | 90.5m |
Cash & Short-Term Investments | 47.8m |
Receivables | 31.7m |
Other Current Assets | 11m |
Non-Current Assets | 117.8m |
PP&E | 112.4m |
Intangibles | 493k |
Other Non-Current Assets | 5m |
Current Liabilities | 55.3m |
Accounts Payable | 7.9m |
Accrued Liabilities | 3.2m |
Other Current Liabilities | 44.2m |
Non-Current Liabilities | 35.2m |
Long-Term Debt | 2.9m |
Other Non-Current Liabilities | 32.2m |
Earnings Waterfall
Mabion SA
Revenue
|
151.7m
PLN
|
Cost of Revenue
|
-37.1m
PLN
|
Gross Profit
|
114.6m
PLN
|
Operating Expenses
|
-47m
PLN
|
Operating Income
|
67.6m
PLN
|
Other Expenses
|
-26.3m
PLN
|
Net Income
|
41.3m
PLN
|
Free Cash Flow Analysis
Mabion SA
MAB Profitability Score
Profitability Due Diligence
Mabion SA's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Score
Mabion SA's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
MAB Solvency Score
Solvency Due Diligence
Mabion SA's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Mabion SA's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MAB Price Targets Summary
Mabion SA
According to Wall Street analysts, the average 1-year price target for MAB is 16.07 PLN with a low forecast of 13.13 PLN and a high forecast of 19.43 PLN.
Shareholder Return
MAB Price
Mabion SA
Average Annual Return | 13.68% |
Standard Deviation of Annual Returns | 117.52% |
Max Drawdown | -86% |
Market Capitalization | 303.5m PLN |
Shares Outstanding | 16 162 326 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Mabion SA is a biotechnology company, which engages in the development and manufacture of biotech drugs. The company is headquartered in Konstantynow Lodzki, Woj. Lodzkie and currently employs 213 full-time employees. The company went IPO on 2010-08-10. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The firm specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. The company focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. The company operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.
Contact
IPO
Employees
Officers
The intrinsic value of one MAB stock under the Base Case scenario is 12.65 PLN.
Compared to the current market price of 18.78 PLN, Mabion SA is Overvalued by 33%.